NUS Enterprise

Point-of-care diagnostics

Technology #2017-342

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
A/Prof Shao Huilin
Managed By
Dr Ler Ser Yeng
Manager (65)66016248
Files and Attachments
Tech Offer [PDF]

Market Opportunity

The nucleic acid market is expected to grow beyond US$4,900 million by end of 2027 with a compound annual growth of 7.5% from 2017-2027. Current detection of pathogen nucleic acids is performed in the centralized clinical laboratories. This is costly, time-consuming and requires trained personnel. Therefore, there is a need for easy-to-use point-of-care diagnostics.

Technology

This is a novel molecular platform that enables point-of-care visual and modular detection of nucleic acids. It has been clinically validated and shown to perform well against a clinical gold standard test (Cobas® HPV) with a high detection accuracy of area under the curve = 0.965 for HPV16 and area under the curve = 0.944 for HPV18. Furthermore, by expanding the intra-subtype coverage, it was able to detect infections in samples that were missed by the commercial test.

Stage of Development

TRL 4

Applications

Initially targeting the markets for diagnosis and screening of infectious diseases. Additional markets can be pursued wherever detection of specific nucleic acids is required:

·  Genetic diseases

·  Cancers

·  Water and air quality monitoring

·  Food and agriculture testing

Advantages

·  Fast (<2 hours)

·  Sensitive (<10 amol)

·  Cheap

·  Can be readily read out with the naked eye and quantified with smartphones.

·  With versatile microfluidic design to complement the modular assay, a diverse array of pathogens on demand can be tested with a plug-in system.